Paramount: Descriptive Subgroup Analyses of Final Overall Survival (OS) for the Phase III Study of Maintenance Pemetrexed (PEM) Versus Placebo (PLB) Following Induction Treatment with PEM Plus Cisplatin (CIS) for Advanced Nonsquamous (NS) Non-Small Cell Lung Cancer (NSCLC)
Reck, M., Paz-Ares, L., De Marinis, F., Molinier, O., Prasad Sahoo, T., Laack, E., John, W., Zimmermann, A., Visseren-Grul, C.M., Gridelli, C.Volume:
23
Journal:
Annals of Oncology
DOI:
10.1016/s0923-7534(20)33787-x
Date:
September, 2012
File:
PDF, 57 KB
2012